Kura Oncology, Inc. (KURA)
| Market Cap | 1.57B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -168.09M |
| Shares Out | 76.18M |
| EPS (ttm) | -2.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 673,679 |
| Open | 21.18 |
| Previous Close | 21.20 |
| Day's Range | 20.47 - 21.37 |
| 52-Week Range | 7.41 - 24.17 |
| Beta | 0.94 |
| Analysts | Strong Buy |
| Price Target | 28.36 (+37.8%) |
| Earnings Date | Aug 1, 2024 |
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpeli... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for KURA stock is "Strong Buy." The 12-month stock price forecast is $28.36, which is an increase of 37.80% from the latest price.
News
Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes –
Life Science Cares San Diego Teams with Kura Oncology to Support Nutritional Needs of the San Diego Community
SAN DIEGO--(BUSINESS WIRE)--Life Science Cares San Diego, a nonprofit organization activating the financial and human capital of the life sciences industry and partnering with local nonprofits to disr...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 07, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines fo...
Kura Oncology to Participate in Jefferies Global Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o...
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in early 2025 – – Breakthrough Therapy Designation to enable expedited review by FDA – SAN DIEG...
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o...
Kura Oncology Reports First Quarter 2024 Financial Results
– Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive prelimina...
Kura Oncology to Report First Quarter 2024 Financial Results
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to comp...
Kura Oncology to Participate in Stifel Targeted Oncology Forum
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
– Company anticipates dosing of KO-2806 in combination with adagrasib in KRASG12C-mutant NSCLC next quarter –
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
– Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome –
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
– KOMET-008 is evaluating ziftomenib in combination with gilteritinib, FLAG-IDA or LDAC in patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged AML –
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Kura Oncology stock jumped another 20% on Tuesday: here's why
Kura Oncology Inc (NASDAQ: KURA) rallied close to 20% this morning after reporting positive preliminary data for a Phase 1 study of its Ziftomenib “in combination with standards of care”. Ziftomenib t...
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
– No differentiation syndrome events reported – – 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML – – 56% CR/CRh with ven/aza in menin inhibitor naïve patients with R/R AML – – 80% of ...
Kura Oncology Announces Oversubscribed $150 Million Private Placement
– Funding from existing investors, including EcoR1 Capital, an affiliate of Deerfield Management and Suvretta Capital – – Pro forma cash, cash equivalents and investments expected to provide runway in...
Kura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical Trial
SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Kura Oncology Reports Third Quarter 2023 Financial Results
– Completion of enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML expected by mid-2024 – – Preliminary data from 20 patients in KOMET-007 combination trial of ziftom...
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
– Ongoing Phase 1 dose-escalation trial of KO-2806 (FIT-001) expected to begin dosing patients in combination with adagrasib by mid-2024 – – Ongoing Phase 1 dose-escalation trial of KO-2806 (FIT-001) ...
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Kura Oncology to Report Third Quarter 2023 Financial Results
SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806
– Phase 1 dose-escalation study to evaluate KO-2806 as a monotherapy and in combination with targeted therapies in KRASG12C-mutant NSCLC and ccRCC –